Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

"We have about eight patients that are in the insurance approval process," she said, for gene therapy treatments for beta thalassemia and sickle cell disease. "It's something that we do expect to ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amwins Group Benefits is now expanding its Gene Therapy Solutions (GTS) program to 15 gene and cell therapies, up from the ...

Editas remains focused on getting its own gene therapy, reni-cel, ready for regulators—with readouts from studies in SCD and transfusion-dependent beta thalassemia due by the end of the year.

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

The company presented proof-of-concept preclinical in vivo hematopoietic stem and progenitor data in humanized mice and outlined its go-forward strategy centering on in vivo LNP-delivered gene ...